Main Predictions Topic Discovery Antistress
🇬🇧 English 🇪🇸 Español 🇩🇪 Deutsch 🇫🇷 Français 🇵🇱 Polski 🇨🇿 Česky 🇨🇳 中文 🇰🇷 한국어

Articles by tag: durvalumab

FDA approval of combination immunotherapy for bladder cancer: durvalumab + BCG

FDA approval of combination immunotherapy for bladder cancer: durvalumab + BCG

FDA approved durvalumab with BCG for high-risk NMIBC. POTOMAC data: 32% risk reduction. Analysis of efficacy, toxicity, and consequences of BCG shortage. Learn more.